SGAM
ALDR

Smith Group Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Smith Group Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,760
Closed -$224K – 497
2017
Q1 		$224K Hold
10,760
– – 0.01% 253
2016
Q4 		$224K Hold
10,760
– – 0.01% 241
2016
Q3 		$353K Sell
10,760
-20
-0.2% -$609 0.01% 208
2016
Q2 		$269K Buy
+10,780
New +$292K 0.01% 223

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Smith Group Asset Management's ALDR Position: Q2 2017 in Review

Smith Group Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 10,760 shares — an estimated $224K sold.

Smith Group Asset Management first reported a position in ALDR in Q2 2016 and held it in 4 quarters. The position peaked at $353K in Q3 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Smith Group Asset Management reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Smith Group Asset Management sold 10,760 Alder Biopharmaceuticals shares in Q2 2017, an estimated $224K.
  • Smith Group Asset Management first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Smith Group Asset Management's Alder Biopharmaceuticals position peaked at $353K in Q3 2016.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Smith Group Asset Management's 13F filing for Q2 2017, filed 2 Aug 2017.